

2019 Understanding Suicide Rate, **Risk Factors and Trends Among Head and Neck Cancer Survivors**

MASCC/ISOO

Annual Meeting on Suppportive Care in Cancer

www.mascc.org/meeting

Follow us on Twitter: @CancerCareMASCC







SAINT LOUIS UNIVERSITY.

Understanding Suicide Rate, Risk Factors and Trends Among Head and Neck Cancer Survivors



Nosa Osazuwa-Peters, BDS, PhD, MPH, CHES 1,2

¹ Saint Louis University School of Medicine, Otolaryngology-Head and Neck Surgery, St. Louis ² Saint Louis University Cancer Center, St. Louis

June 21, 2019

DISCLOSURES

None





Background








Past Year Suicidal Thoughts and Behaviors Among U.S. Adults (2016)

Data Courtesy of SAMHSA

Background

Suicide





SUPPORTIVE CARE MAKES EXCELLENT CANCER CARE POSSIBLE

Suicide by Method (2016) Data Courtesy of CDC				
Suicide Method	Number of Deaths			
Total	44,965			
Firearm	22,963			
Suffocation	11,642			
Poisoning	6,698			
Other	3,662			



Estimated new cancer cases in the US, 2018

1,762,450





Estimated Numbers of Cancer Survivors as of January 1, 2019

16.9 million





What do cancer patients die from?

- Index cancers
- Second primaries
- Non-cancer competing causes:
 - Cardiovascular disease...
 - **Suicide**



CANCER-ASSOCIATED SUICIDE

 50% greater risk than general US population

Lifetime suicide risk





CANCER-ASSOCIATED SUICIDE: WHY?

- Acute and late toxicities
- Unmet psychosocial needs
- Esthetics and functionality
- Pain and fear of recurrence





21-23 JUNE SAN FRANCISCO SUPPORTIVE CARE

MAKES EXCELLENT CANCER CARE POSSIBLE


WHY HEAD AND NECK CANCER?

- Depression common
- Choice between esthetics and function
- Facial disfigurement and body image issues
- Financial toxicity





WHY THE STUDY?



More∇

Primary Cancer vs Competing Causes of Death in Survivors of Head and Neck Cancer

Matthew C. Simpson, MPH¹; Sean T. Massa, MD¹; Eric Adjei Boakye, MA²; Jastin L. Antisdel, MD¹; Katherine A. Stamatakis, PhD, MPH³; Mark A. Varvares, MD⁴; Nosayaba Osazuwa-Peters, BDS, MPH, CHES¹


≫ Author Affiliations

JAMA Oncol. 2018;4(2):257-259. doi:10.1001/jamaoncol.2017.4478



Each year post-HNC diagnosis: 26% increase in the odds of dying from competing causes

Figure. Conditional Probability Plot Showing the Time Point During Years of Follow-up When Competing Causes of Death Surpass Primary Head and Neck Cancer (HNC) as the Leading Cause of Death in the HNC Population



The plots cross at approximately 56 months after diagnosis.



Oral Oncology 65 (2017) 8-15



Contents lists available at ScienceDirect

Oral Oncology

journal homepage: www.elsevier.com/locate/oraloncology





Competing causes of death in the head and neck cancer population



Sean T. Massa ^{a,*}, Nosayaba Osazuwa-Peters ^a, Kara M. Christopher ^b, Lauren D. Arnold ^c, Mario Schootman ^c, Ronald J. Walker ^a, Mark A. Varvares ^d

ARTICLE INFO


ABSTRACT

^a Department of Otolaryngology - Head and Neck Surgery, Saint Louis University School of Medicine, St. Louis, MO, United States

^b Cancer Center, Saint Louis University School of Medicine, St. Louis, MO, United States

^cCollege for Public Health and Social Justice, Department of Epidemiology, Saint Louis University, St. Louis, MO, United States

Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, United States





Oral Oncology 81 (2018) 29-34



Contents lists available at ScienceDirect

Oral Oncology

journal homepage: www.elsevier.com/locate/oraloncology





Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis



Nosayaba Osazuwa-Peters^{a,b,c,*}, Lauren D. Arnold^{b,c}, Travis M. Loux^c, Mark A. Varvares^d, Mario Schootman^c



^a Saint Louis University School of Medicine, Department of Otolaryngology-Head and Neck Surgery, St. Louis, United States

b Saint Louis University Cancer Center, St. Louis, United States

^c Saint Louis University College for Public Health and Social Justice, Department of Epidemiology and Biostatistics, St. Louis, United States

^d Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, United States

 Male to female ratio: new cases/deaths: 3:1

 Male to female ratio: suicide in general US population: 4:1

 Male to female HNC suicide ratio: ≈ 6:1 Poisson regression relative risk model for head and neck cancer suicide, 1975-2014 (n = 1036).

	aRR	95% CI
Gender		
Male	5.74	3.88, 8.50
Female		Ref
HPV-relatedness**		
HPV-related	0.87	0.58, 1.29
Not HPV-related		Ref
Age		
≥70	2.74	1.71, 4.39
60-69	2.55	1.61, 4.04
40–59	2.16	1.37, 3.41
18–39		Ref
Race		
Hispanic	0.25	0.14, 0.43
Non-Hispanic Black	0.20	0.12, 0.33
Non-Hispanic Other	0.38	0.25, 0.56
Non-Hispanic White		Ref
Marital status		
Divorced/separated	1.30	1.00, 1.69
Never married	1.09	0.83, 1.43
Widowed	1.48	1.10, 1.99
Married		Ref



CANCER CARE POSSIBLE





Original Article

Suicide Risk Among Cancer Survivors: Head and Neck Versus Other Cancers

Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES^{1,2,3}; Matthew C. Simpson, MPH¹; Longwen Zhao, MS³; Eric Adjei Boakye, MA, PhD(c)⁴; Stephanie I. Olomukoro, MD, MPH⁵; Teresa Deshields, PhD, ABPP⁶; Travis M. Loux, PhD³; Mark A. Varvares, MD, FACS⁷; and Mario Schootman, PhD³

BACKGROUND: Cancer survivors face psychosocial issues that increase their risk of suicide. This study examined the risk of sui across cancer sites, with a focus on survivors of head and neck cancer (HNC). **METHODS:** The Surveillance, Epidemiology, and

•	Pancreatic cancer:
	86.4/100,000 PY

Head and neck: 63.4/100,000 PY

	Cancer survivors (n=4,219,097)	Frequency of suicide (n=4,493)	Suicide mortality rate per 100,000 person-years	p-
Cancer site (%)			• *************************************	<0
Pancreas	119108 (2.8)	93 (2.1)	86.4	1
Head and Neck	151167 (3.6)	404 (9.0)	63.4	
Lung and Bronchus	572239 (13.6)	553 (12.3)	59.3	
Stomach	76225 (1.8)	81 (1.8)	48.9	_
Liver	80779 (1.9)	47 (1.1)	41.1	
Urinary Bladder Brain and Other	184884 (4.4)	315 (7.0)	35.5	
Nervous System	60265 (1.4)	42 (0.9)	29.8	
Testis	30709 (0.7)	55 (1.2)	27.2	
Prostate	736360 (17.5)	1229 (27.4)	26.6	
Colon and Rectum Non-Hodgkin	453390 (10.8)	495 (11.0)	25.0	
Lymphoma Melanoma of the	191342 (4.5)	209 (4.7)	24.7	
Skin	191615 (4.5)	256 (5.7)	23.3	
Leukemia	114537 (2.7)	93 (2.1)	22.8	
Kidney and Renal				
Pelvis	141344 (3.4)	139 (3.1)	22.3	
Ovary (excluding				
certain histologies) Hodgkin	71596 (1.7)	39 (0.9)	15.4	
Lymphoma	26868 (0.6)	24 (0.5)	15.1	
Cervix Uteri	47853 (1.1)	32 (0.7)	13.3	
Thyroid	123696 (2.9)	60 (1.3)	8.4	
Female Breast	700808 (16.6)	287 (6.4)	7.0	
Corpus and Uterus, NOS	144312 (3.4)	40 (0.9)	5. <mark>3</mark>	



2019 21-23 JUNE SAN FRANCISCO

SUPPORTIVE CARE MAKES EXCELLENT CANCER CARE POSSIBLE




Fully adjusted model: head and neck cancer vs. all non-head and neck cancer sites combined

		Adjusted Rate Ratio (aRR)	95% Confidence Interval
Site			
	Non-HNC (ref)	1.00	1.00
Sex	Head and neck cancer	1.97	1.77, 2.19
	Female (ref) Male	1.00 5.63	1.00 5.17, 6.13




Fully adjusted model: risk of suicide among male HNC survivors vs.





Fully adjusted model: risk of suicide among female HNC survivors vs.





SUMMARY OF FINDINGS

Pancreatic cancer (86.4/100,000 PY);
 HNC (63.4/100,000 PY)



 HNC survivors two times likelier to die by suicide than other survivors (aRR=1.97, 95% CI 1.77, 2.19)

 Only male pancreatic cancer survivors had higher suicide risk than HNC (aRR=1.53, 95% CI 1.21, 1.95)



TAKE-HOME POINTS

Pancreatic cancer (86.4/100,000 PY);
 HNC (63.4/100,000 PY)



 HNC survivors two times likelier to die by suicide than other survivors (aRR=1.97, 95% CI 1.77, 2.19)

 Only male pancreatic cancer survivors had higher suicide risk than HNC (aRR=1.53, 95% CI 1.21, 1.95)

CLINICAL/PUBLIC HEALTH IMPLICATIONS

1. Provide evidence for incorporating suicide prevention clinics into the mainstream of individualized cancer survival care plan



2. Provide evidence to support including lifelong suicide surveillance in the NCCN guidelines, making it standard medical practice

LIMITATIONS AND STRENGTHS

- Retrospective data (difficulty establishing causality)
- Difficulty delineating self-inflicted injury/suicide vs. accidents/adverse effects (potential misclassification)
- Comorbidities, e.g., depression not available in SEER
- No information on existing psychiatric conditions, family history of suicide, or use of medications
- HPV-tumor status classified through anatomic proxy



ACKNOWLEDGMENTS

Collaborators/Coauthors:

- Lauren D Arnold, PhD, MPH
- Matthew C Simpson, MPH
- Sean T Massa, MD
- Longwen Zhao, MS
- Eric Adjei Boakye, MA, PhD(c)
- Ronald J Walker, MD
- Kara Christopher, MS, MPH, PhD(c)
- Stephanie Olomukoro, MD, MPH
- Travis Loux, PhD
- Mario Schootman, PhD
- Mark A Varvares, MD, FACS





THANK YOU!



